LGM
TPTX

Logos Global Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Logos Global Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400,000
Closed -$31.2M – 74
2021
Q2 		$31.2M Buy
400,000
+260,000
+186% +$19.2M 2.62% 12
2021
Q1 		$13.2M Buy
+140,000
New +$16.6M 1.29% 17

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Logos Global Management's TPTX Position: Q3 2021 in Review

Logos Global Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2021, closing a stake of 400,000 shares — an estimated $31.2M sold.

Logos Global Management first reported a position in TPTX in Q1 2021 and held it in 2 quarters. The position peaked at $31.2M in Q2 2021. 190 funds tracked by Wall St. Rank hold TPTX as of Q3 2021.

  • Logos Global Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Logos Global Management sold 400,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $31.2M.
  • Logos Global Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Logos Global Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $31.2M in Q2 2021.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Logos Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.